Benefits Plans - Prescription Drug Plan: Drug Plan Updates and New Drug Releases - Drug Reviews

Page last updated: Wednesday, 26-May-2010 20:51:28 EDT

January – April 2009

Following are the drug considerations that were reviewed and determined for formulary inclusion and Tier placement by the U-M Pharmaceutical Benefits Advisory Committee. The chart combines the January - April 2009 drug releases.

Drug Name Indication Preferred Drug List Action
Afinitor (everolimus) Renal Cancer
No
Tier 2, PA
Apriso (mesalamine) Ulcerative Colitis 
No
Tier 2
Astepro (azelastine) Allergic Rhinitis
Yes
Tier 3
Banzel (rufinamide) Anticonvulsant
Yes
Tier 2, PA
degarelix Prostate Cancer
No
Tier 3
Epiduo  Acne
No
Tier 3, PA
Kapidex (dexlansoprazole) GERD
Yes
Non-Covered
Mozobil (plerixafor) Blood Cancers
No
Tier 2, PA
PrandiMet Diabetes
Yes
Tier 3
Rapaflo (silodosin) BPH
Yes
Non-Covered
Ryzolt (tramadol Ext-rel) Pain
Yes
Tier 3
Toviaz (fesoterodine) Overactive Bladder
Yes
Non-Covered
Trilipix (fenofibrate) Cholesterol
No
Tier 3
Uloric (febuxostat) Gout
No
Tier 2, Step Therapy
Vectical Ointment (calcitriol) Psoriasis
No
Tier 3
Limitations
The University of Michigan in its sole discretion may modify, amend, or terminate the benefits provided with respect to any individual receiving benefits, including active employees, retirees, and their dependents. Although the university has elected to provide these benefits this year, no individual has a vested right to any of the benefits provided. Nothing in these materials gives any individual the right to continued benefits beyond the time the university modifies, amends, or terminates the benefit. Anyone seeking or accepting any of the benefits provided will be deemed to have accepted the terms of the benefits programs and the university's right to modify, amend or terminate them.